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BRIEF REVIEW
Effects of Post-Translational Modifications  
of Fibrinogen on Clot Formation, Clot Structure, 
and Fibrinolysis
A Systematic Review
Judith J. de Vries, Charlotte J.M. Snoek, Dingeman C. Rijken, Moniek P.M. de Maat
OBJECTIVE: Post-translational modifications of fibrinogen influence the occurrence and progression of thrombotic diseases. In 
this systematic review, we assessed the current literature on post-translational modifications of fibrinogen and their effects 
on fibrin formation and clot characteristics.
APPROACH AND RESULTS: A systematic search of Medline, Embase, Cochrane Library, and Web of Science was performed to 
find studies reporting post-translational modifications of fibrinogen and the effects on clot formation and structure. Both in 
vitro studies and ex vivo studies using patient material were included. One hundred five articles were included, describing 11 
different modifications of fibrinogen. For the best known and studied modifications, conclusions could be drawn about their 
effect on clot formation and structure. Oxidation, high levels of nitration, and glycosylation inhibit the rate of polymerization, 
resulting in dense clots with thinner fibers, while low levels of nitration increase the rate of polymerization. Glycation showed 
different results for polymerization, but fibrinolysis was found to be decreased, as a consequence of increased density and 
decreased permeability of clots. Acetylation also decreases the rate of polymerization but results in increased fiber diameters 
and susceptibility to fibrinolysis. Other modifications were studied less or contrasting results were found. Therefore, substantial 
gaps in the knowledge about the effect of post-translational modifications remain.
CONCLUSIONS: Overall, post-translational modifications do affect clot formation and characteristics. More studies need to be 
performed to reveal the effects of all post-translational modifications and the effects on thrombotic diseases. Expanding 
the knowledge about modifications of fibrinogen can ultimately contribute to optimizing treatments for thrombotic diseases.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: fibrin ◼ fibrinogen ◼ fibrinolysis ◼ polymerization ◼ systematic review
The architecture and properties of a thrombus are an important determinant of the disease burden and mortality associated with cardiovascular diseases. 
One of the main determinants of thrombus characteristics 
is variations in the fibrinogen molecule, which affect the 
clotting rate, architecture of the fibrin matrix and its sus-
ceptibility to fibrinolysis. Therefore, it is essential to know 
the effect of variability in the fibrinogen molecule on the 
coagulation cascade and the clot characteristics. Fibrino-
gen is a glycoprotein that is synthesized by hepatocytes 
and circulates in the blood of healthy individuals at con-
centrations between 2 and 4 g/L. Fibrinogen consists 
of 2 sets of 3 different polypeptide chains: 2-Aα, 2-Bβ, 
and 2-γ chains, which are held together by 29 disulfide 
bridges.1 The genes encoding for these chains (FGA, 
FGB, and FGG) are found in a cluster of 65 kilobases on 
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the human chromosome 4 (4q23-q32).2 In the fibrinogen 
molecule, different main structural regions can be identi-
fied.3 The central E region contains the amino acid ter-
mini of the polypeptide chains and this is also the place 
where thrombin cleaves. The 2 distal nodules (D regions) 
contain the carboxyl termini of the Bβ and γ chains and 
are connected to the E region by 2 α-helical coiled-coil 
domains. The carboxyl termini of the Aα chains form the 
αC-regions, which are more flexible and mobile.4
The final step of the coagulation cascade is the cleav-
age by thrombin between arginine and glycine residues in 
the Aα and Bβ chain in the E region, which releases fibri-
nopeptides A and B.5 This results in the formation of fibrin 
monomers and initiation of polymerization. Thrombin also 
activates factor XIII, which cross-links γ chains or α chains 
from neighboring fibrin molecules, thereby enhancing the 
stability of the fibrin network.6 Fibrinolysis of the fibrin 
network starts when a tissue-type plasminogen activator 
converts plasminogen into plasmin, which cleaves fibrin 
after lysine residues. Susceptibility to fibrinolysis is highly 
influenced by the structure of the clot.7 Thicker fibers, 
reduced branching, and larger pores increase the perme-
ability and susceptibility to fibrinolysis, which is considered 
anti-thrombotic. However, thinner fibers, more branching, 
and smaller pores make the clot less permeable and more 
resistant to lysis by plasmin (prothrombotic).8
Fibrinogen Heterogeneity
Fibrinogen heterogeneity is the result of several types of 
variation: genetic polymorphisms, alternative mRNA pro-
cessing, proteolytic cleavage, environmental factors, and 
post-translational modifications of fibrinogen.9–11 The dif-
ferent combinations of these determinants lead to more 
than a million forms of fibrinogen within a healthy individ-
ual.12,13 Post-translational modifications affect the func-
tion of fibrinogen, thereby influencing clot formation, the 
clot structure and susceptibility to clot lysis. These effects 
have consequences for the occurrence and progression 
of thrombotic diseases. The post-translational modifica-
tions which are discussed in this systematic review will be 
shortly introduced below. In Figures 1 and 2, an overview 
of the sites of modifications in the fibrinogen chains and 
the biochemistry of these modifications are shown.
Post-Translational Modifications
Oxidation
One of the modifications of fibrinogen is oxidation. Oxi-
dative stress occurs in the human body when a high 
amount of reactive oxygen species are produced (eg, by 
immune cells, pro-oxidant enzymes, and during oxygen 
metabolism) which are not sufficiently detoxified by anti-
oxidants.14 Reactive oxygen species can be produced 
as a consequence of exogenous insults, for example, 
radiation from UV-light or smoking.15 Among the reac-
tive oxygen species are superoxide anion, hydrogen per-
oxide, hypochlorous acid, and hydroxyl radical.14 These 
different reactive oxygen species react with and cause 
damage to a wide range of components of the cells, for 
example, proteins and DNA. Consequences of oxida-
tion of proteins are the formation of carbonyl groups 
and the modification of amino acids (eg, methionine is 
converted into methionine sulphoxide and tyrosine into 
dityrosine; Figure 2).16,17 Compared with other plasma 
proteins, fibrinogen is especially susceptible to oxida-
tion. It was shown that fibrinogen is 20 times more sus-
ceptible to oxidation than albumin, the most abundant 
plasma protein.18 A recent article identified the amino 
acids in fibrinogen which are oxidized by ozone.19 Previ-
ously, other articles have identified amino acids oxidized 
by photo-oxidation and hypochlorous acid.20 In Figure 1, 
we show the amino acids which were identified by at 
least 2 ways of oxidation or which were oxidized above 
50% using 50 µmol/L ozone.
Nitration
Oxidative stress also leads to the production of reac-
tive nitrogen species.15 Superoxide anion reacts with 
nitric oxide to produce the highly reactive peroxynitrite. 
In addition, the reaction of oxygen with nitric oxide and 
peroxynitrite results in the formation of other reactive 
nitrogen species, for example, nitrite and nitronium ion. 
Nitration of fibrinogen mainly affects tyrosine residues, 
resulting in the formation of 3-nitrotyrosine.21,22 Also cys-
teine residues can be affected, resulting in the formation 
of 3-nitrocysteine (Figure 2).
Modification by Carbohydrates
Glycosylation is the enzymatic process in which sugars 
(glycans or polysaccharides) are attached to proteins in 
an ATP (adenosine triphosphate)-dependent manner. 
Nonstandard Abbreviations and Acronyms
MI myocardial infarction
Highlights
• Variations in fibrinogen affect the occurrence and 
progression of thrombotic diseases.
• Post-translational modifications of fibrinogen affect 
clot formation, clot characteristics, and susceptibility 
to fibrinolysis.
• For the best known post-translational modifications 
of fibrinogen, conclusions regarding their effect on 
clot characteristics can be drawn.
• Additional research is needed to elucidate the 
effects of all post-translational modifications of 
fibrinogen on clot characteristics.
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Glycosylation is needed at certain sites in a protein to 
function properly. Sialylation is a form of glycosylation 
in which sialic acid is bound at the end of a sugar chain 
of a glycoprotein. Each Bβ and γ chain of fibrinogen 
has 1 N-glycosylation site, which can contain zero, 1, or 
2 sialic acids (Figure 1).23,24 Normally, ≈6 sialic acid res-
idues are present in each fibrinogen molecule.25 Abnor-
mal glycosylation has been related to aging and certain 
diseases; for example, patients with liver disease show 
an increased level of sialic acid content of their fibrino-
gen molecules.26,27 Glucose is known to nonenzymati-
cally bind to proteins, often resulting in an impairment 
of its functions, in a process called glycation. Glycation 
occurs in patients with high levels of glucose in their 
blood, for example, in uncontrolled diabetes mellitus. 
Normal glucose levels are 5 mmol/L (90 mg/dL), but 
this can go up to 20 mmol/L (360 mg/dL) in patients 
with diabetes mellitus.28 Also at normal glucose levels, 
glycation can occur. This is associated with oxidative 
stress, for example, observed during inflammation or in 
age-related diseases.29 In fibrinogen, glycation is found 
to occur at lysine residues (Figure 1).30
Acetylation
Acetylation is the attachment of an acetyl group to amino 
acids. In vivo, acetylation occurs at N-termini of polypep-
tide chains by Nt-acetyltransferases or at the ε-amino 
group of lysine residues by lysine acetyltransferases 
(Figure 2).31 Both processes have important physiological 
functions. Acetylation can also be caused by the intake 
of aspirin, which is known to exert its beneficial effects 
in cardiovascular disease by acetylating serine residues 
in the enzyme platelet cyclooxygenase. In fibrinogen and 
other coagulation proteins, aspirin can acetylate lysine 
residues, affecting their functions (Figure 1).30,32
Phosphorylation
Phosphorylation is the attachment of a phosphate 
group to an amino acid by protein kinases. Phosphory-
lation and dephosphorylation (by protein phosphatases) 
of proteins affect the structure and have important con-
sequences for protein function.33 Many enzymes are, 
for example, activated or deactivated by (de)phosphor-
ylation and in many signaling pathways, phosphoryla-
tion plays a crucial role. In fibrinogen, phosphorylation 
occurs mainly on serine and threonine located in the 
Aα chain (Figure 1).34,35 It is shown that fetal fibrino-
gen is phosphorylated to a higher degree than adult 
fibrinogen, suggesting a functional importance of phos-
phorylation.34 In addition, phosphorylation of fibrinogen 
increases after surgery, potentially contributing to pre-
vention of bleeding.36
Other Modifications
High levels of the plasma protein homocysteine results in 
the nonenzymatic post-translational modification homo-
cysteinylation. Homocysteine has a free sulfhydryl group, 
with which it forms disulfide bonds with cysteine resi-
dues in proteins. Also, lysine residues can be modified, 
by the metabolite homocysteine thiolactone.37 Homocys-
teine is produced in the metabolism of methionine, and it 
is thought that even a small increase in the plasma level 
is a risk factor for cardiovascular disease.38 Homocyste-
ine levels can be increased as a consequence of renal 
dysfunction, vitamin deficiencies, or medication affect-
ing homocysteine metabolism.38 Homocysteine levels in 
Figure 1. Known sites of post-translational modifications in the fibrinogen chains for the most studied modifications.
Schematic representation of the fibrinogen chains with the known sites of the post-translational modifications shown in lines with different 
colors. The letter and number indicate the type of amino acid which is modified and the position of the amino acid, respectively. The colored 
blocks correspond to the different regions of the fibrinogen molecule.
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plasma higher than 15 µmol/L are considered hyperho-
mocysteine and levels above 100 µmol/L are classified 
as homocysteinuria.39 In human fibrinogen, 3 lysine resi-
dues (Lys562 in the Aα chain, Lys344 in the Bβ chain, 
and Lys385 in the γ chain) were shown to be homocys-
teinylated, both in vitro and in vivo.40
Citrullination is the catalytic conversion of the amino 
acid arginine into citrulline by the enzyme peptidyl argi-
nine deiminase. This post-translational modification is 
important in patients with rheumatoid arthritis, systemic 
lupus erythematosus, and other autoimmune diseases 
because autoantibodies in these diseases often attack 
Figure 2. Biochemistry of the post-translational modifications.
For each modification discussed in this review, 1 or 2 amino acids with the biochemical changes are depicted.
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citrullinated proteins.41 Citrullination of fibrinogen poten-
tially plays a role in the increased risk of thrombosis 
observed in rheumatoid arthritis.42 Using in vitro experi-
ments, multiple arginine residues, mainly in the Aα chain 
and a few in the Bβ chain, were identified that are citrul-
linated by 2 different peptidylarginine deiminases.43
Carbamylation of proteins mainly occurs when amino 
acids interact with isocyanic acid, for example, during 
chronic kidney disease or atherosclerosis.44 Isocyanic 
acid forms when urea decomposes into ammonium 
and cyanate, cyanate subsequently converts into isocy-
anic acid. Another source of cyanate is the thiocyanate 
metabolism, in which thiocyanate in the presence of 
hydrogen peroxide is converted into cyanate by myelo-
peroxidase.44 Interaction of free amino acids or lysine 
residues with isocyanic acid results in the formation of α-
carbamyl-amino acids or ε-carbamyl-lysine (homocitrul-
line), respectively.44 Homocitrulline differs from citrulline 
by only one additional methylene group.
Finally, guanidinylation is the conversion of an amino 
group into a guanidine group, for example, happening in 
patients on hemodialysis.45 Mostly, lysine residues are 
affected, which are converted into homoarginine. These 
last 2 post-translational modifications are studied less 
for fibrinogen, but because fibrinogen is a very abundant 
plasma protein, these modifications will most likely also 
affect fibrinogen.
It is important to know the effect of these post-trans-
lational modifications on clot formation, the clot struc-
ture, and susceptibility to fibrinolysis since these clot 
characteristics affect the development and progression 
of thrombosis and thromboembolic disease.46,47 With 
this knowledge, therapies to prevent or treat these dis-
eases by normalizing clot structure or susceptibility to 
fibrinolysis can be optimized. During the past 70 years, 
multiple research groups have investigated the effects 
of these post-translational modifications. However, con-
tradictory results are reported for the effects of cer-
tain modifications studied by different research groups. 
Therefore, the aim of this systematic review was to 
make an overview of the results of studies investigating 
the effect of post-translational modifications of fibrino-
gen on clot formation, clot structure, and susceptibility 
to fibrinolysis, to be able to draw tentative conclusions 
or identify the knowledge gaps.
METHODS
This systematic review was performed according to the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines.48
Article Search
We conducted a systemic literature search in the Embase, 
Medline-Ovid, Cochrane Library, and Web of Science data-
bases on April 18, 2019; and the search was repeated on 
October 8, 2019. The search strategy included the different 
post-translational modifications in combination with fibrino-
gen and the characteristics we were interested in (eg, clotting 
time, clot structure, density, or permeability; see Methods in the 
online-only Data Supplement for the full search). No limit was 
set on the year of publication.
Study Selection
After deduplication, the search yielded 1278 results. Two 
researchers (J.J. de Vries and C.J.M. Snoek) independently 
screened these articles. First, relevant articles were included 
based on title and abstract. The included abstracts were sub-
sequently read full text and articles that did not match the 
research question were excluded. In addition, conference 
abstracts, reviews, and articles not available in full text (in 
English) were excluded. Additional relevant articles identified 
while reading the full-text articles were also assessed for inclu-
sion and included if there was a match with the research ques-
tion. In case of disagreement, consensus about the articles was 
reached through discussion.
Data Extraction
To prevent bias, data were independently extracted from the 
articles by 2 researchers (J.J. de Vries and C.J.M. Snoek). The 
following data was collected: first author, publication year, 
method of experiments (which type of fibrinogen or plasma 
was used and how it was modified) and effects of the modifi-
cation compared to control (clottability, cleavage by thrombin, 
rate of polymerization, initiation of polymerization or lag phase, 
maximal absorbance, diameter of fibrin fibers, stiffness, per-
meability, density, cross-linking, plasmin digestion of fibrino-
gen, and clot lysis).
RESULTS
Study Selection
A total of 1640 articles was found in the literature search. 
After elimination of duplication, 1278 articles were 
screened based on title and abstract (Figure 3). From 
the 183 articles read full text, we included 66 articles. In 
addition, while reading these articles full text, we found 
39 other relevant articles in the references which were 
also included. The majority of these extra articles which 
did not show up in our literature search were old studies 
or did not use the terms for the modification in the title or 
abstract, which might explain why they did not come up 
in the search. In total, we identified 105 studies.
Study Characteristics
Most of the studies were performed in vitro with com-
mercial purified fibrinogen, however, purified fibrinogen 
or plasma from patients was also used in a substantial 
number of studies. Especially studies investigating acety-
lation used healthy volunteers or patients taking aspirin 
to study the effect of acetylation on fibrinogen. Also, 
studies investigating the effect of other modifications 
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used material from patient groups in which the modifica-
tion was known to be increased (eg, oxidation in myocar-
dial infarction [MI] patients, glycation in diabetes mellitus 
patients, and sialylation in patients with liver disease). 
Twelve clot characteristics were studied in this systematic 
review. Clottability was used to describe the percentage 
of fibrinogen which is able to clot. Cleavage by thrombin 
describes the amount or rate of fibrinopeptide release 
from fibrinogen by thrombin. The rate of polymerization 
is reported when clotting time or the rate of aggregation 
was measured. Initiation of polymerization was mostly 
measured by the length of the lag phase, the time before 
clotting starts (when lag phase increases, initiation of 
polymerization is decreasing). Maximum turbidity means 
the maximum value of absorbance measured in turbid-
ity assays. The diameter of fibrin fibers was determined 
using the mass-length ratio or measuring thickness of 
fibers on microscopy images. The stiffness of the clot 
was measured using rheology or thromboelastography. 
Permeability describes the permeability of the clot, while 
density corresponds to the amount of fibers in a certain 
area. Cross-linking is mainly measured by measuring the 
amount and rate of formation of γ- or α-dimers. Plasmin 
digestion of fibrinogen means the breakdown of fibrino-
gen molecules by plasmin. Finally, clot lysis describes the 
degree or rate of fibrinolysis of the clot. Of these char-
acteristics, most information was available for the rate 
of polymerization and maximum turbidity. The findings of 
all studies per modification are summarized in the Table.
Oxidation of Fibrinogen
Oxidation is the most studied post-translational modifica-
tion of fibrinogen (31 articles, Table I in the online-only 
Data Supplement). Most studies used (human) fibrino-
gen and added a compound or condition that oxidizes 
fibrinogen (reactive oxygen species, ozone, or illumina-
tion). However, the conditions used in vitro show a lot of 
Figure 3. PRISM (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of study selection.
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variation. A few studies used fibrinogen from patients with 
diseases known to increase oxidative stress, and there-
fore the level of fibrinogen oxidation is increased49–53 
(shown in Table I in the online-only Data Supplement 
below the thick line). Except for Paton et al,49 the stud-
ies which used patient material do not show large differ-
ences compared to the in vitro studies.
The clottability of oxidized fibrinogen was decreased 
after oxidation in 2 studies.54,55 When light, radiation, or 
peroxynitrite was used to oxidize fibrinogen, no difference 
in cleavage by thrombin was found (3 studies).55–57 How-
ever, when fibrinogen was oxidized by reactive carbonyl 
compounds or ascorbate and iron, the cleavage by throm-
bin was decreased (2 studies).56,58 This suggests that the 
manner of oxidation influences the effects, probably by 
affecting different sites in fibrinogen. The rate of polym-
erization of fibrinogen after oxidation was mostly found 
to be significantly decreased compared to nonoxidized 
fibrinogen (in 25 of the 34 experiments). The in vitro stud-
ies reporting an increased rate of polymerization used 
relatively high concentrations of oxidative compounds, 
which might explain the discrepancy.59,60 In almost all 
experiments, the initiation of polymerization was signifi-
cantly delayed (6 out of 9) and the maximum absorbance 
measured in turbidity assays was significantly decreased 
(15 out of 19). In correspondence with this, the diameter 
of the fibrin fibers was found to be significantly smaller in 
8 of the 12 experiments. Only a few studies report con-
tradictory results: a shorter lag phase and increased max-
imum absorbance or diameter.49,61,62 The study done by 
Rosenfeld et al61 found a significantly shorter lag phase 
and thicker fibrin fibers after oxidation of fibrinogen with 
ozone. The thicker fibers are also reported in 62, where the 
same researchers used a similar method of oxidation. It 
is possible that oxidation by ozone differently affects the 
fibrinogen molecule than other methods of oxidation. The 
final study which shows contradictory results compared to 
the majority of the studies used purified fibrinogen from 
MI patients 24 to 96 hours after the heart attack and 
compared clot characteristics between patients in dif-
ferent quartiles of plasma protein carbonyl values (rep-
resentative of oxidative modifications and correlated to 
fibrinogen carbonyl content).49 The authors themselves 
describe that the fibrinogen in other studies is probably 
more highly oxidized than their plasma samples, which 
would suggest that a low level of oxidation increases the 
ability of fibrinogen to clot. However, there is quite a broad 
range in concentrations of reactive compounds used in 
the other 30 studies, which gives a broad range of oxida-
tion and most studies show a decreased ability of clotting. 
In addition, it can be appreciated in Table I in the online-
only Data Supplement that incubating fibrinogen with rel-
atively high concentrations of oxidative compounds shows 
an increased rate of polymerization, which would suggest 
the opposite: fibrinogen from the MI patients is oxidized 
to a higher degree instead of a lower degree. The other 
study that used fibrinogen from MI patients used blood 
drawn from patients 6 months after the event,50 which 
is very different from 24 to 96 hours after MI. Although 
comparable levels of fibrinogen carbonyl content were 
reported in both studies, this difference in time after MI 
can be one of the reasons for the discrepancy between 
the 2 studies.
Other properties of the fibrin clot are studied in fewer 
articles. In general, a decreased stiffness (6 out of 7), 
lower permeability (4 out of 5), and higher density of fibrin 
clots (4 out of 8) were found after oxidation. Two stud-
ies found an increase in cross-linking after oxidation,63,64 
while another study reported no difference.16 Digestion 
of fibrinogen by plasmin was found to be decreased 
after oxidation by concentrations of peroxynitrite higher 
than 100 µmol/L, whereas lower concentrations did not 
show significant differences.65 Fibrinolysis was found 
to be significantly decreased by most studies (6 out of 
9),16,50,51,66,67 but also no difference (one study) or an 
increase (2 studies) in fibrinolysis was reported.53,68,69
Table. Overview of the Effects of the Different Modifications
Modification
Fibrin Polymerization Clot Characteristics Fibrinolysis
References
Clotta-
bility
Cleavage 
by  
Thrombin
Rate of 
Polymeriza-
tion
Initiation of 
Polymeriza-
tion
Maximum 
Turbidity
Diameter 
of Fibers
Stiffness 
of Clot
Perme-
ability Density
Cross-
Linking
Plasmin 
Digestion of 
Fibrinogen
Clot 
Lysis
Oxidation ↓ =/↓ ↓ ↓ ↓ ↓ ↓ ↓ ↑ ↑  ↓ 16,19,49–78
Nitration  = ↑/↓ ↑/↓ ↑/↓      =  21,57,65,70,79–86
Glycosylation  = ↓ ↓ ↓ ↓    = =  25–27,87–99
Glycation ↑ = =/↑ = =/↑ = = ↓ ↑ = ↓ ↓ 28,100–114
Acetylation  = ↓  ↑/↓ ↑ ↓ ↑ ↓   ↑ 32,71,115–125
Phosphorylation     ↑/↓ ↓     ↓  35,36,126–132
Homocysteinyl-
ation
  =/↓      ↑ =  ↓ 39,133–137
Citrullination ↓ ↓ ↓  ↓ ↓   ↓    138–140
Carbamylation   ↓ ↓ ↓ ↓   ↑ ↓  ↓ 141
Guanidinylation      ↓  ↓     45
D
ow
nloaded from
 http://ahajournals.org by on March 18, 2020
BRIEF REVIEW
 - VB
de Vries et al Post-Translational Modifications of Fibrinogen
Arterioscler Thromb Vasc Biol. 2020;40:554–569. DOI: 10.1161/ATVBAHA.119.313626 March 2020  561
Overall, oxidation seems to decrease the rate of 
clotting and results in more dense fibrin clots with thin-
ner fibers which are less permeable. No conclusions 
can be drawn about the degree of cross-linking, diges-
tion of fibrinogen or fibrinolysis, since only a few stud-
ies are done which all report different results. However, 
since most studies report a more dense fibrin clot with 
lower permeability, fibrinolysis is most likely decreased 
after oxidation.
Nitration of Fibrinogen
A post-translational modification that is relatively similar 
to oxidation and often studied in combination with oxida-
tion is nitration of fibrinogen. We identified 12 studies 
on nitration of fibrinogen (Table II in the online-only Data 
Supplement), of which 3 are also included in the oxida-
tion table (65 and 57 use peroxynitrite to study oxidation, 
which is also a nitrating agent and70 performed both oxi-
dating and nitrating experiments). In Table II in the online-
only Data Supplement, the upper part shows the in vitro 
studies, arranged in order of increasing concentrations 
per nitrating compound used. Four studies also included 
experiments with fibrinogen from coronary artery dis-
ease patients,70,79 smokers,80 or healthy volunteers taking 
lipopolysacharides,81 all resulting in increased levels of 
nitration of fibrinogen (shown in the lower part of Table II 
in the online-only Data Supplement).
No significant effect of nitration on cleavage by throm-
bin was found in 2 studies.57,70 The rate of polymerization 
is generally found to be increased for nitrated fibrinogen 
from patients (5 out of 5 studies with patients) or fibrin-
ogen nitrated by low levels of nitrifying agents. Except 
for one study, all experiments using high concentrations 
(>10 µmol/L peroxynitrite or 100 µmol/L nitronium 
fluoroborate) to nitrate fibrinogen showed a decreased 
rate of polymerization. Ding et al82 used a concentration 
of peroxynitrite slightly lower than 10 µmol/L but also 
added increasing concentrations of manganese, which 
is known to increase fibrinogen nitration, explaining why 
they also find a decreased rate of polymerization. Helms 
et al83 used 5 µmol/L ProliNONOate to nitrate fibrino-
gen by the action of nitric oxide and found a decreased 
rate of polymerization, although not significant. There is 
one study that shows an increased rate of polymeriza-
tion, although a high concentration of peroxynitrite (1 
mmol/L) was used.21 This might be caused by a rela-
tively low level of nitration found in this study; only 1.13 
nitrotyrosine residues per fibrinogen molecule formed 
in contrast to levels up to 8 nitrotyrosine residues per 
fibrinogen molecule in other studies where high con-
centrations of peroxynitrite were used. Initiation of 
polymerization and maximum absorbance of turbidity 
measurements correspond to the results found for rate 
of polymerization; if the rate of polymerization was found 
to be increased, initiation of polymerization and maximum 
turbidity were also increased. The diameter of the fibrin 
fibers was found to be thinner after nitration with a high 
concentration of peroxynitrite84 or in fibrinogen from 
coronary artery disease patients,70 while another study 
with fibrinogen from smokers reported no difference80 
and the study in which fibrinogen was nitrated by nitric 
oxide showed thicker fibers.83 Also the stiffness of the 
clot showed all different results (decrease, no differ-
ence or increase in stiffness).70,80,83 Permeability and 
cross-linking were investigated by only one study, which 
showed both characteristics to be increased.70 Density is 
shown to be higher in one study84 and lower in another83 
after nitration in vivo. Digestion of fibrinogen or lysis of 
the fibrin clot by plasmin is shown to be similar65,70 or 
decreased after nitration of fibrinogen.65,80
Overall, a low level of nitration increases the rate of 
fibrinogen polymerization, while increased nitration of 
fibrinogen decreases the rate of polymerization. The 
few studies studying the other clot characteristics find 
opposing results, probably also caused by different 
degrees of nitration or by the presence of other oxida-
tive modifications that can occur upon treating fibrinogen 
with peroxynitrite.
Modification of Fibrinogen by Carbohydrates
We identified only 3 studies on the effect of glycosylation 
on fibrinogen (Table III in the online-only Data Supple-
ment). One ex vivo study used fibrinogen from subjects 
of varying age, since aging increases the glycosylation of 
fibrinogen.27 However, there were no differences in clot 
characteristics between older people (with a high level 
of glycosylation) and younger people.27 Two other in vitro 
studies used another approach to study the effect of gly-
cosylation of fibrinogen: the glycosylation of fibrinogen 
was inhibited during the production of fibrinogen in rabbit 
hepatocytes87 or sugars were removed from fibrinogen 
using peptide-N-(N-acetyl-β-glucosaminyl)asparagine 
amidase.88 The first approach resulted in no differ-
ence in rate of polymerization, while the second study 
showed an increased rate of polymerization and maxi-
mum turbidity, thicker fibers and a more permeable clot, 
while cross-linking and fibrinogen digestion by plasmin 
were not affected by removal of glycosylation. Another 
in vitro study (not included in Table III in the online-only 
Data Supplement) was found in which fibrinogen was 
incubated with different sugars, investigating the lectin 
activity of fibrinogen. In addition, the effect of incubat-
ing fibrinogen with these different sugars was studied. A 
decreased rate of polymerization, decreased maximum 
turbidity and diameter of the fibers and a decreased 
cross-linking were found after incubation with different 
sugars.142
A specific form of glycosylation, sialylation, was 
studied by 13 articles. Four studies with fibrinogen 
from patients with specific diseases which are shown 
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to increase the levels of sialic acid all presented a 
decreased rate of polymerization and initiation of 
polymerization.26,89–91 In other experiments, a different 
approach was used, namely removing sialic acid from 
fibrinogen. In addition, one article used fibrinogen from 
pregnant women, having a lower degree of sialylation.91 
This desialylation resulted in increased rates of polymer-
ization in 5 out of 6 studies, confirming the inhibitory role 
of sialic acid on polymerization.
Overall, glycosylation of fibrinogen results in 
decreased rates of polymerization and thinner fibers. 
There is not enough evidence to say something about 
the effect of glycosylation on the other characteristics of 
the fibrin clots.
Glycation of fibrinogen occurs in conditions with a high 
glucose concentration. We identified 16 studies investi-
gating the effect of glucose binding on fibrinogen (Table 
IV in the online-only Data Supplement). Fibrinogen was 
incubated with glucose in vitro, or fibrinogen or plasma 
from patients with diabetes mellitus was used to assess 
the effects of glycation. Table IV in the online-only Data 
Supplement is sorted on glucose concentration used in 
vitro in the upper part of the table. Below the thick line, 
the studies using fibrinogen or plasma from patients with 
diabetes mellitus are sorted on the use of fibrinogen or 
plasma and type of patients with diabetes mellitus used.
After glycation, the clottability of fibrinogen was found 
to be similar (in one study) or increased (in 3 studies) 
compared to control fibrinogen. The 4 in vitro stud-
ies investigating the cleavage by thrombin reported no 
difference between glycated and control fibrinogen. 
However, fibrinogen from patients with type 2 diabetes 
mellitus showed an increased cleavage of fibrinopeptide 
B compared to control subjects.100 The studies show 
contradictory results regarding the rate of polymeriza-
tion, initiation of polymerization, and maximal turbidity. 
Different concentrations of glucose were used to glycate 
control fibrinogen, or fibrinogen or plasma from both 
patients with type 1 and type 2 diabetes mellitus were 
used, which might explain these differences. The diam-
eter of the fibers did not change after glycation, but this 
was only investigated by 2 studies.100,101 The stiffness of 
the clot was also found to be similar for fibrinogen or 
plasma from patients with diabetes mellitus and controls 
in 2 studies.101,102 Three out of 4 studies measuring per-
meability found a decreased permeability after glycation 
and density is mostly shown to be increased (in 3 out of 4 
studies). Most studies (7 out of 9) found no difference in 
cross-linking between glycated and control fibrinogen or 
between fibrinogen from patients with diabetes mellitus 
and control subjects. Finally, the majority of the results 
showed a decreased digestion of fibrinogen (3 out of 
4) and fibrinolysis of the clot (4 out of 5) after glycation.
Overall, studies investigating glycation show different 
results regarding the polymerization, probably caused by 
the different conditions of modification used. The few 
studies which are performed regarding the other char-
acteristics of fibrin clots from glycated fibrinogen show a 
decreased permeability, increased density, no detectable 
effect on thickness of fibers, stiffness or cross-linking 
and decreased fibrinolysis of the clot after glycation.
Acetylation of Fibrinogen
Another modification is the acetylation of fibrinogen, 
which is mostly studied in the context of aspirin intake. 
We identified 13 studies, of which 6 did experiments with 
fibrinogen or plasma from patients or healthy volunteers 
who took aspirin (below the thick line in Table V in the 
online-only Data Supplement). The clottability and cleav-
age by thrombin were shown to be similar for control 
fibrinogen and fibrinogen acetylated in vitro.115–117 The 
rate of polymerization and maximum turbidity was mostly 
found to be significantly decreased after fibrinogen 
acetylation or ingestion of aspirin compared to nonacety-
lated fibrinogen (5 out of 9 studies). Only plasma from 
healthy volunteers taking a high dose of aspirin twice 
daily showed an increased polymerization.32 The other 
3 studies showed no effects of acetylation on the rate 
of polymerization. Most experiments show a significantly 
increased diameter of the fibrin fibers after acetyla-
tion (7 out of 9). In correspondence with this, all stud-
ies agree that the permeability is increased (8 studies), 
the density is lower (3 studies) and susceptibility to clot 
lysis is increased (6 studies). It becomes clear that tak-
ing a low dose of aspirin is more beneficial than a higher 
dose since the high dose does not affect the fiber thick-
ness and permeability of clots in 2 studies testing both 
doses.118,119 It is suggested that a high dose of aspirin can 
result in the formation of salicyclic acid molecules, which 
block acetylation of fibrinogen and, therefore, inhibit the 
beneficial effects of aspirin on clot structure.120 In con-
clusion, the acetylation of fibrinogen decreases fibrin 
polymerization and increases permeability and suscep-
tibility to fibrinolysis.
Phosphorylation of Fibrinogen
The effect of phosphorylation or dephosphorylation of 
fibrinogen on clotting was studied by 9 research articles 
(Table VI in the online-only Data Supplement). These are 
all studies performed >20 years ago, no recent data were 
available. In most studies, fibrinogen was phosphorylated 
by incubating fibrinogen with kinases, although there is 
one study that uses fibrinogen from 5 patients after a 
hip surgery, who have elevated phosphorylation levels of 
fibrinogen.36 It appears that phosphorylation by protein 
kinase A or C reduces the maximum turbidity and thick-
ness of fibers, while phosphorylation by casein kinase 
II increases maximum turbidity and the fiber diameter. 
The patients after hip surgery also showed an increased 
maximum turbidity and fiber diameter, which would 
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suggest casein kinase II is the enzyme responsible for 
phosphorylation of fibrinogen in vivo.36 However, only 5 
patients were used, and more research is needed to con-
firm this hypothesis. The digestion of fibrinogen by plas-
min was shown to be decreased in all studies, it made 
no difference which kinase was used. Another strategy 
to study the role of phosphorylation on fibrinogen was to 
remove the phosphate group from normal fibrinogen by 
alkaline phosphatase. It was found that dephosphoryla-
tion increases the maximum turbidity and diameter of 
fibrin fibers in 3 studies, while plasmin digestion was 
not affected (only one study). Finally, also the revers-
ibility of these effects was investigated by dephos-
phorylating phosphorylated fibrinogen. It was shown 
that dephosphorylation increases maximum turbidity 
and diameter of fibrin fibers (and therefore normalizes 
back to normal after phosphorylation by protein kinase 
C and higher than normal in the case of casein kinase-
phosphorylated fibrinogen).36,126,127 However, plasmin 
digestion of fibrinogen stayed reduced and is therefore 
not reversible.36,127,128
In conclusion, the effect of phosphorylation on polym-
erization and the diameter of fibrin fibers depends on the 
kinase used to phosphorylate fibrinogen in vitro. Ex vivo, 
it was shown that increased phosphorylation of fibrino-
gen results in increased clot turbidity and fiber diameters, 
although this was only investigated by one study using a 
limited amount of patients.
Other Modifications of Fibrinogen
Six studies were identified in which the effect of homo-
cysteinylation of fibrinogen was studied (Table VII in 
the online-only Data Supplement). Plasma from a rab-
bit model of homocystinuria showed an increased rate 
of polymerization and decreased fiber diameter,133 while 
human fibrinogen and plasma incubated with homo-
cysteine showed a decrease in rate of polymerization, 
decreased maximum turbidity, and no change in fiber 
diameter.39 However, when plasma was incubated with 
higher levels of homocysteine (500 µmol/L), an increase 
in maximum turbidity and fiber diameter was observed.134 
These differences are probably the result of different 
concentrations of homocysteine, the use of fibrinogen or 
plasma and the difference between in vitro and in vivo 
situations. Clot density is observed to be increased by 3 
studies and also agreement is reached over a decreased 
susceptibility to fibrinolysis after homocysteinylation in 
5 studies. Stiffness of the clot was found to be signifi-
cantly increased after incubation of plasma with 50 to 
500 µmol/L homocysteine.135
Two studies on citrullination of fibrinogen reported an 
inability of fibrinogen to clot because thrombin is not able 
to cleave off the fibrinopeptides of citrullinated fibrino-
gen and, therefore, no polymerization occurs138,139 (Table 
VII in the online-only Data Supplement). A more recent 
article showed clotting after citrullination of fibrinogen 
and observed a decreased rate of polymerization, turbid-
ity, fiber diameter, and density.140
Carbamylation was studied in only one article in which 
carbamylation was found to decrease the ability of fibrin-
ogen to clot, resulting in fibrin clots with thinner fibers, a 
higher density, less cross-linking, and decreased suscep-
tibility to fibrinolysis.141
Finally, one article was found in which fibrinogen 
was modified by guanidinylation. The level of guanidi-
nylation is increased in patients on hemodialysis.45 
Both clots formed from plasma from these patients and 
fibrinogen to which o-methylisourea-bisulfate solution 
was added to guanidinylate fibrinogen showed clots 
with thinner fibers.45 Also, the permeability of clots 
formed from plasma from patients on hemodialysis 
was decreased. The kinetics of polymerization were not 
investigated in this study.
DISCUSSION
In this systematic review, 105 research articles were 
identified that investigated the effects of post-transla-
tional modifications of fibrinogen on polymerization, clot 
structure, and fibrinolysis.
For oxidation, most research reported a decreased 
rate of polymerization, which results in more dense fibrin 
clots with thinner fibers and lower permeability. This 
results in clots that are more resistant to fibrinolysis, 
and therefore, prothrombotic. The mechanism by which 
oxidation affects clotting is thought to be oxidation of 
methionine residues in the αC region, which is involved in 
lateral aggregation. The αC region is proven to be most 
vulnerable to oxidation by ozone and hypochlorite.19,143 
Weigandt et al16 identified methionine residue at position 
476 in the αC region to be oxidized by hypochlorite. Con-
version of Met476 into methionine sulfoxide was shown 
to impair dimerization of αC domains, thereby inhibiting 
lateral aggregation.144
An interesting finding by Wang et al64 was the obser-
vation that the stiffness of the clot measured at low fre-
quencies is higher for oxidized fibrinogen compared to 
the control, while increasing the frequency at which stiff-
ness is measured results in a lower value for oxidized 
fibrinogen. This difference implicates that the effect of 
oxidation on the stiffness can change corresponding 
to the conditions used in the measurement. This is an 
interesting finding, since blood flow and shear stress in 
the human body can also be variable. Therefore, it would 
be interesting to perform more experiments studying the 
effect of oxidation of clot stiffness measured during dif-
ferent degrees of shear stress.
It is hard to distinguish between nitration and oxida-
tion, but in this systematic review, we separated these 
modifications. However, it should be noted that nitration 
and oxidation often occur simultaneously. In general, 
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nitration of fibrinogen using low concentrations of nitrat-
ing agents (low level of nitration) results in an increased 
rate of polymerization and higher maximum turbidity. The 
same results are found when fibrinogen nitrated in vivo 
is compared to control fibrinogen without nitration. How-
ever, high levels of nitration in vitro decrease the rate of 
polymerization and maximum turbidity. This shows that 
we need to be careful translating in vitro results to the 
in vivo situation. The other clot characteristics are less 
well studied for the effect of nitration. It is shown that 
nitration of fibrinogen results in the formation of nitro-
tyrosines in the part of the Bβ chain which is involved in 
lateral aggregation.80 It is suggested that a low degree of 
nitration results in a gain of function of fibrinogen, having 
an increased rate of polymerization. When fibrinogen is 
nitrated with high concentrations of nitrating compounds, 
there might be too much nitrotyrosine formation which 
blocks lateral aggregation.
Glycosylation, and specifically sialylation, inhibits the 
rate of fibrin polymerization and leads to thinner fibers, 
which was shown both by increasing glycosylation and 
deglycosylation of fibrinogen. It is suggested that sialic 
acid inhibits polymerization by electrostatic repulsion 
between fibrin monomers.92 In normal conditions, calcium 
binds these sialic acid residues, thereby neutralizing this 
inhibitory effect. However, during liver disease, sialylation 
levels are increased, leading to insufficient neutralization of 
sialic acid by calcium and therefore inhibition of polymer-
ization and thinner fibrin fibers.92 There has not been done 
enough research to draw conclusions about the effect 
of glycosylation on the other clot characteristics, such as 
stiffness of the clot, cross-linking, and permeability.
Glycation of fibrinogen showed contradictory effects 
on the polymerization, which might be caused by the dif-
ferent conditions in which this modification was tested 
(in vitro or fibrinogen or plasma from type 1 or type 2 
diabetes mellitus patients). Therefore, more research 
is needed to determine the effect of glycation on fibrin 
polymerization and to evaluate if this effect is similar in 
diabetic patients. Few studies investigated other charac-
teristics of fibrin clots and showed an increased density 
and decreased permeability and fibrinolysis of the clot 
after glycation, which corresponds to the resistance to 
clot lysis seen in diabetic patients.145 In this systematic 
review, only studies are included which specifically inves-
tigated the glycation of fibrinogen (either by using puri-
fied fibrinogen or measuring fibrinogen glycation when 
plasma was used). However, there are multiple studies 
that used plasma from patients with diabetes mellitus to 
study clot characteristics, without quantifying fibrinogen 
glycation. These studies also show a decreased perme-
ability and impaired fibrinolysis in clots from diabetic 
patients.146,147 It is known that the risk to develop major 
thrombotic diseases, for example, MI, stroke, or deep vein 
thrombosis, is increased in diabetes mellitus, due to the 
inflammatory and prothrombotic environment, of which 
the latter can partly be ascribed to the glycation of fibrin-
ogen.148 Besides the increased density and decreased 
permeability, another reason for resistance to fibrinolysis 
might be the glycation of specific lysine residues in plas-
min-sensitive coiled-coil regions of fibrinogen, thereby 
occupying the binding sites of plasmin.30
Acetylation was shown by most studies to decrease 
the rate of fibrin polymerization and increase permeability 
and susceptibility to fibrinolysis. This is beneficial in the 
prevention and treatment of thrombosis and thromboem-
bolic diseases, since a more permeable clot increases 
the susceptibility to fibrinolytic treatment. Acetylation as 
a consequence of aspirin intake is shown to target lysine 
residues, thereby disturbing the charge distribution of the 
fibrinogen molecule and affecting polymerization, result-
ing in clots with thicker fibers and increased permeabil-
ity.120 In addition, acetylation of lysine residues involved 
in cross-linking might be the cause of the decreased 
cross-linking seen in 121, which further contributes to the 
increased permeability of fibrin clots.30
It has been hypothesized that there is a competition 
between acetylation of amino acids by aspirin and glyca-
tion in diabetes mellitus, resulting in aspirin resistance 
in patients with diabetes mellitus.149 However, identifica-
tion of the lysine residues affected by both modifications 
showed no overlap between these sites.30 Another study 
describes that taking aspirin can prevent the disadvanta-
geous effects of oxidation. It was shown that acetyla-
tion of lysine residues in fibrinogen prevents the effects 
of oxidation of fibrinogen.71 The question whether this is 
due to competition remains to be answered.
The effect of in vitro phosphorylation of fibrinogen was 
different for the specific kinases used. Phosphorylation by 
casein kinase II showed similar results (increased maxi-
mum turbidity and thicker fibers after phosphorylation) 
as fibrinogen with an increased phosphorylation purified 
from patients, which suggests this kinase plays a role 
in fibrinogen phosphorylation in vivo. Also, the sequence 
specificity of type II casein kinases corresponds to the 
sequences around the phosphorylated amino acids.34 It 
was reported that casein kinase II phosphorylates serine 
and threonine residues in the Aα and γ’ chain.35 Although 
protein kinase C also phosphorylates serine residues in 
the carboxyl-terminal part of the Aα chain,150 the effects 
of phosphorylation are different (decrease in maximum 
turbidity and fiber thickness), which suggests that amino 
acids at different positions are involved. To determine 
the effects of phosphorylation of fibrinogen, further 
studies are required which investigate which kinase is 
responsible for in vivo phosphorylation of fibrinogen, to 
use this information in in vitro experiments. In addition, 
fibrinogen phosphorylated in vivo can be used to investi-
gate the effect of phosphorylation on clot characteristics. 
For example, no information is available on the effect of 
phosphorylation on clot stiffness, permeability, and sus-
ceptibility to fibrinolysis.
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Studies on homocysteinylation of fibrinogen did not 
find consistent results in the polymerization, probably 
because different (mainly nonphysiological) concentra-
tions of homocysteine were used with either fibrinogen 
or plasma. It would be recommended in further studies 
to use physiological homocysteine levels for homocyste-
inylation of fibrinogen to be certain about the effects on 
polymerization and fiber diameter. However, the studies 
did all show an increase in density and decrease in fibri-
nolysis after homocysteinylation. This can be explained by 
the finding that homocysteinylation of fibrinogen occurs 
mostly on lysines in the Aα chain which are involved in 
plasmin binding and cleavage.136,137
In 2 studies on citrullination of fibrinogen, no clots 
could be formed due to the citrullination of arginine res-
idues in the N-terminus of the Aα and Bβ chain.138,139 
Since arginine residues are the cleavage site of thrombin, 
this modification inhibits the cleavage of fibrinopeptides 
by thrombin and formation of fibrin monomers, which 
explains the absence of clot formation. However, it is 
interesting to note that patients with rheumatoid arthritis 
(high levels of citrullinated fibrinogen) have an increased 
risk of thrombosis and do not have an increased risk of 
bleeding. This suggests that there is (increased) clot for-
mation when fibrinogen is citrullinated in vivo. It is pos-
sible that the degree of citrullination in the performed in 
vitro studies is too high and, therefore, not relevant for 
the in vivo situation. A more recent study was indeed able 
to form clots with citrullinated fibrinogen and observed 
a decreased rate of polymerization, decreased turbidity, 
thinner fibers, and a decreased density when clots were 
formed from citrullinated fibrinogen.140 Since this is only 
one study, these results need to be confirmed. In addi-
tion, ex vivo research with fibrinogen from rheumatoid 
arthritis patients would also be interesting.
Both for carbamylation and guanidinylation only one 
study was found, suggesting these modifications result 
in more dense clots with thinner fibers which are less 
susceptible to fibrinolysis. This corresponds to the in vivo 
situation seen in diseases in which these modifications 
occur (kidney disease or atherosclerosis).
Most studies included in this review are performed in 
vitro, sometimes with high concentrations of chemicals to 
induce the post-translational modifications. This makes it 
challenging to translate these findings to the in vivo situ-
ation. However, for most modifications, also in vivo work 
has been done, which mostly shows the same effects as 
found in vitro (except for nitration, as described above). 
Another source of variation between the studies is the 
variation in techniques used to study certain clot charac-
teristics. Especially older articles used different methods 
to determine, for example, clotting time and clot lysis time 
(by visual inspection), while in more recent studies tur-
bidity assays are used. Another example is the assess-
ment of the diameter of the fibrin fibers, techniques used 
are, for example, the turbidity assay to calculate the 
mass-length ratio or electron microscopy. However, we 
conclude that the different techniques used to measure 
the clot characteristics did not cause different observed 
effects of the post-translational modifications.
Although reviews are written about the effect of oxi-
dative or other post-translational modifications, no recent 
systematic review is performed in which the effects of 
modifications are systematically shown as in our system-
atic review. A quantitative meta-analysis on the effect of 
post-translational modifications on clot characteristics 
was not possible, since there is too much variation in the 
way of modification and measurements of the different 
effects. Another limitation of this review is that studies 
might be missed in our literature search. However, we 
think that by identifying additional articles while reading 
our articles in full text, we covered a sufficient part of 
articles available on this subject.
CONCLUSIONS
In conclusion, there is knowledge about the effects of 
most post-translational modifications of fibrinogen on 
clot characteristics, especially about the best known 
post-translational modifications (oxidation, glycosylation, 
and acetylation). There are still many unanswered ques-
tions which deserve attention in upcoming research. 
For example, nitration shows different effects on fibrin 
polymerization and clot structure, potentially caused by 
the degree of nitration, which needs to be elucidated. 
Current research on glycation also shows contradictory 
effects on fibrin polymerization. For phosphorylation, in 
vivo studies could provide more information on which 
kinase is used in the body to phosphorylate fibrinogen 
and what the effect of this modification is on polymeriza-
tion and clot structure. To investigate the effect of other 
(less known) modifications, for example, homocyste-
inylation and citrullination, only a few studies have been 
performed, which need confirmation. Expanding the 
knowledge about these modifications of fibrinogen can 
ultimately contribute to optimizing treatments for throm-
botic diseases.
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